MXPA04012685A - Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. - Google Patents

Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.

Info

Publication number
MXPA04012685A
MXPA04012685A MXPA04012685A MXPA04012685A MXPA04012685A MX PA04012685 A MXPA04012685 A MX PA04012685A MX PA04012685 A MXPA04012685 A MX PA04012685A MX PA04012685 A MXPA04012685 A MX PA04012685A MX PA04012685 A MXPA04012685 A MX PA04012685A
Authority
MX
Mexico
Prior art keywords
insulin resistance
ortho
treatment
benzoic acid
acid derivatives
Prior art date
Application number
MXPA04012685A
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04012685A publication Critical patent/MXPA04012685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Abstract

La presente invencion proporciona un compuesto de la formula (I), en donde n es 0, 1 o 2; R1 representa halo, un grupo alquilo de 1 a 4 atomos de carbono el cual esta opcionalmente sustituido con uno o mas fluoro, un grupo alcoxi de 1 a 4 atomos de carbono que esta opcionalmente sustituido con uno o mas fluoro y en donde cuando n es 2, los sustituyentes R1 pueden ser los mismos o diferentes; R2 reopresenta un grupo alquilo de 2 a 7 no ramificado; R3 representa hidrogeno u OCH3 ; y W representa oxigeno o azufre, y la sales farmaceuticamente aceptables y los profarmacos de los mismos, a los procesos para la preparacion de tales procesos a su utilidad en el tratamiento de condiciones clinicas asociadas con resistencia a la insulina, a los metodos para su uso terapeuticos y a las composiciones farmaceuticas que los contienen.
MXPA04012685A 2002-06-20 2003-06-17 Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. MXPA04012685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201936A SE0201936D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
PCT/GB2003/002591 WO2004000294A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
MXPA04012685A true MXPA04012685A (es) 2005-03-23

Family

ID=20288294

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04012685A MXPA04012685A (es) 2002-06-20 2003-06-17 Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.

Country Status (26)

Country Link
EP (1) EP1517679B1 (es)
JP (1) JP2005535618A (es)
KR (1) KR20050014015A (es)
CN (1) CN1307988C (es)
AR (1) AR039714A1 (es)
AT (1) ATE385790T1 (es)
AU (1) AU2003240100B2 (es)
BR (1) BR0311839A (es)
CA (1) CA2490684A1 (es)
DE (1) DE60319082T2 (es)
DK (1) DK1517679T3 (es)
ES (1) ES2299703T3 (es)
HK (1) HK1074779A1 (es)
IL (1) IL165670A0 (es)
IS (1) IS7626A (es)
MX (1) MXPA04012685A (es)
NO (1) NO20045223L (es)
NZ (1) NZ536971A (es)
PL (1) PL375080A1 (es)
PT (1) PT1517679E (es)
RU (1) RU2288912C2 (es)
SE (1) SE0201936D0 (es)
TW (1) TW200407114A (es)
UA (1) UA76627C2 (es)
WO (1) WO2004000294A1 (es)
ZA (1) ZA200409693B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
EP1517883B8 (en) 2002-06-20 2008-05-21 AstraZeneca AB Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
PL219045B1 (pl) * 2010-10-16 2015-03-31 Inst Chemii Organicznej Polskiej Akademii Nauk Nowe estry (acyloksymetylo)akrylamidu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowanie
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use

Also Published As

Publication number Publication date
EP1517679B1 (en) 2008-02-13
PT1517679E (pt) 2008-04-21
DE60319082D1 (de) 2008-03-27
SE0201936D0 (sv) 2002-06-20
EP1517679A1 (en) 2005-03-30
CN1307988C (zh) 2007-04-04
NO20045223L (no) 2005-03-17
NZ536971A (en) 2006-05-26
CA2490684A1 (en) 2003-12-31
AU2003240100A1 (en) 2004-01-06
RU2004135543A (ru) 2005-08-10
RU2288912C2 (ru) 2006-12-10
BR0311839A (pt) 2005-04-05
CN1674883A (zh) 2005-09-28
ATE385790T1 (de) 2008-03-15
DE60319082T2 (de) 2009-01-29
WO2004000294A1 (en) 2003-12-31
JP2005535618A (ja) 2005-11-24
IL165670A0 (en) 2006-01-15
ES2299703T3 (es) 2008-06-01
HK1074779A1 (en) 2005-11-25
AR039714A1 (es) 2005-03-09
ZA200409693B (en) 2005-10-11
KR20050014015A (ko) 2005-02-05
PL375080A1 (en) 2005-11-14
AU2003240100B2 (en) 2006-06-01
UA76627C2 (en) 2006-08-15
DK1517679T3 (da) 2008-05-19
IS7626A (is) 2005-01-05
TW200407114A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
TW200508180A (en) Therapeutic agents
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
SE0202462D0 (sv) Novel use
GB0206860D0 (en) Compounds
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
ZA200501098B (en) Novel use of benzothiazole derivatives
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
GB0411056D0 (en) Organic compounds
ATE399753T1 (de) Amide als pyruvatdehydrogenaseinhibitoren
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA05010020A (es) Derivados de oxamida.
HRP20050779A2 (en) Supstituted benzoylureidopyridyl-piperidine and pyrrolidine carboxylic acid derivatives, method for the production thereof and the use thereof
CA2489834A1 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
MXPA04012685A (es) Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
SE0104333D0 (sv) Therapeutic agents
SE0101978D0 (sv) New compounds
SE0201837D0 (sv) Chemical compounds
MXPA05013717A (es) Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
SE0201935D0 (sv) Therapeutic agents
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
SE9901530D0 (sv) Novel compounds
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa

Legal Events

Date Code Title Description
FG Grant or registration